Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL7AP75 (Ribosomal protein L7a pseudogene 75) is classified as a pseudogene, meaning it is a non-coding genomic DNA sequence that resembles the functional gene encoding ribosomal protein L7a but does not produce a functional protein product[5][8]. Pseudogenes generally arise by gene duplication or retrotransposition and are typically transcriptionally inactive or, if transcribed, non-functional[2][4]. Most have no established biological function, disease association, or utility as a drug target. There is no evidence that RPL7AP75 is involved in any cellular pathway, nor are there known drugs, biomarkers, or disease links. The proper protein-coding gene related to this pseudogene is RPL7A, which encodes a component of the 60S ribosomal subunit, but RPL7AP75 itself is not a protein or cellular target[1][3][5][8]. RPL7AP75 is not a druggable or therapeutic target, nor does it encode a protein, act as a receptor, enzyme, or have other molecular target properties. Its only 'role' is as a processed pseudogene annotated in the human genome[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7a pseudogene 75 (RPL7AP75).